US 12,221,426 B2
Inhibitory material against human body-derived nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like, and anticancer agent comprising same as effective ingredient or pharmaceutical composition comprising same as effective ingredient for treatment of hyperlipidemia
Bong-Jin Lee, Seoul (KR); Kyu-Yeon Lee, Seoul (KR); Sang Jae Lee, Seoul (KR); Dong-Gyun Kim, Seoul (KR); Joo Youn Lee, Daejeon (KR); Kwan-Young Jeong, Daejeon (KR); Heui Cherl Yang, Daejeon (KR); Hyeon-Kyu Lee, Daejeon (KR); and Hyoun Sook Kim, Gyeonggi-do (KR)
Assigned to Seoul National University R&DBFoundation, Seoul (KR); Korea Research Institute of Chemical Technology, Daejeon (KR); and National Cancer Center, Gyeonggi-do (KR)
Appl. No. 17/271,354
Filed by SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR); KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, Daejeon (KR); and NATIONAL CANCER CENTER, Gyeonggi-do (KR)
PCT Filed Aug. 29, 2019, PCT No. PCT/KR2019/011094
§ 371(c)(1), (2) Date Feb. 25, 2021,
PCT Pub. No. WO2020/046020, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 10-2018-0103008 (KR), filed on Aug. 30, 2018; and application No. 10-2019-0105425 (KR), filed on Aug. 27, 2019.
Prior Publication US 2021/0253544 A1, Aug. 19, 2021
Int. Cl. C07D 277/32 (2006.01); A61P 3/06 (2006.01); A61P 35/00 (2006.01); A61K 31/426 (2006.01)
CPC C07D 277/32 (2013.01) [A61P 3/06 (2018.01); A61P 35/00 (2018.01)] 2 Claims
OG exemplary drawing
 
1. A compound, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is
(Z)-4-((3-((3-(carboxymethyl)-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)-4′-fluorobiphenyl-4-yloxy)methyl)benzoic acid or
(Z)-2-(5-(2-(2-bromobenzyloxy)-4-hydroxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid.